EUVIMEDEUVIMED entdecken
Open Access

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management

Morie A Gertz iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Morie A Gertz. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Diagnosis Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients and is found in most IgM MGUS patients. MYD88 is not required for the diagnosis. Risk Stratification Age, hemoglobin level, platelet count, β 2 microglobulin, LDH, and monoclonal IgM concentrations are characteristics that are predictive of outcomes. Risk‐Adapted Therapy Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab‐monotherapy is inferior to regimens that combine it with bendamustine, an alkylating agent, a proteosome inhibitor, or a BTK inhibitor. The preferred Mayo Clinic induction is either rituximab and bendamustine (without rituximab maintenance) or zanubrutinib. Management of Refractory Disease Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, Bruton Tyrosine Kinase inhibitors, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaHumansRituximabBendamustine HydrochlorideMyeloid Differentiation Factor 88Antibodies, MonoclonalParaproteinsRisk AssessmentImmunoglobulin M

Substanzen

RituximabBendamustine HydrochlorideMyeloid Differentiation Factor 88Antibodies, MonoclonalParaproteinsImmunoglobulin M

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Morie A Gertz

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Gertz, M. A. (2023). Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology. https://doi.org/10.1002/ajh.26796

Vancouver

Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2023. doi:10.1002/ajh.26796

BibTeX
@article{Gertz2023,
  author = {Gertz, Morie A},
  title = {Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26796}
}
Kostenlos starten →